Pfizer Lyme vaccine shows 73% efficacy but misses key
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pfizer and Valneva's Lyme vaccine cut cases by 73% in a Phase 3 trial, showing meaningful effectiveness (STAT+).
- The vaccine missed its primary statistical endpoint due to the confidence interval falling below the pre-specified threshold, complicating regulatory review despite overall solid data and safety (STAT+ Matthew Herper, Pharmalittle).
- A new Parkinson’s startup is developing personalized neuron replacement therapies (STAT+).
- Insmed is working to expand the use of Arikayce earlier in disease treatment (STAT+).
- Apogee is touting a longer-lasting drug for eczema (STAT+).
- Geopolitical tensions are beginning to strain drug supply chains, a concern also noted by Pharmalittle (STAT+).
Why it matters: A highly effective Lyme vaccine faces a tricky regulatory path, impacting public health and vaccine accessibility.
Ask SkimNews
